Grete Biotech's Recombinant Batroxobin Injection Receives Clinical Trial Approval in China on May 22

GateNews
According to Haixiang Pharma's announcement on May 22, Grete Biotech, a company in which Haixiang holds an investment stake, received formal approval from China's National Medical Products Administration (NMPA) to conduct clinical trials for recombinant batroxobin injection, a novel biologic drug. The approved indications target bleeding management in spinal fusion and joint replacement surgeries.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments